Ventana
FDA Approves Astellas' Vyloy, Chemo in First-Line CLDN18.2-Positive Gastric Cancer With Roche CDx
Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.
FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer
The FDA also approved Roche's Ventana FOLR1 (FOLR1-2.1) RxDx Assay as a companion diagnostic to select patients for treatment with Elahere.
PD-L1 Test Comparison Finds Varying Ability to ID Bladder Cancer Patients Who Benefit From Tecentriq
A post hoc analysis suggests that patients who are PD-L1 high by Roche's SP142 test are more likely to live longer with Tecentriq than those deemed high expressers by Agilent's 22C3 test.
Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq
The test gained European approval to identify PD-L1-expressing non-small cell lung cancer patients eligible for treatment with Roche's checkpoint inhibitor.
Roche Nabs FDA Label Expansion for Ventana CDx Panel
The immunohistochemistry companion diagnostic helps identify patients with solid tumors that are deficient in DNA mismatch repair.